Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819552 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL24891256 | 0.90 | HSD11B1 (0.46) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL13548814 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL13179250 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL13462652 | 0.87 | GNAI3 (0.59) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL10080978 | 0.87 | GNAI3 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL7733573 | 0.87 | HSD11B1 (0.47) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL19416662 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL27268804 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 | |
| SCHEMBL22737188 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2GNAI3GNAO1GNAI1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849135-B2 | USP14 inhibitors for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2528911-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9745321-B2 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2016-07-28 | — | — | US | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2014116228-A1 | USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2011094545-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | PIK3CA, WEE1, TKFC | SMN1; SMN2 4341/4885GNAI3 837/4885GNAO1 1122/4885 |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | SMN1; SMN2 623/4885GNAI3 208/4885GNAO1 44/4885 |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSME3, PSMB11 | SMN1; SMN2 307/4885GNAI3 2473/4885GNAO1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.